Opioid Half-lives and Hemlines: The Long and Short of Fashion.

Abstract

In fashion, the most variable style element is the hemline - ranging from ultra-short (hip-high miniskirt) to ultra-long (floor-length).* In anesthesiology, there has been similar fashion in opioid use, with the most variable element being the elimination half-life - ranging from ultra-short (remifentanil) to ultra-long (methadone). Nominally, the former is 0.6 hr, while that of the latter is 24–36 hr. Opioid use in cardiac surgery has been a particular focus.1–4 The pioneering work of Lowenstein and colleagues introduced high-dose morphine anesthesia for cardiac surgery.1 Since then, opioid-based anesthetic techniques for on-pump and off-pump coronary artery and valvular cardiac surgery have become de rigueur. Fentanyl largely supplanted morphine due to greater cardiovascular stability.2,3 The introduction of “fast-track” cardiac surgery created a new focus on rapid recovery, earlier extubation, and faster discharge from the intensive care unit and hospital. Coinciding with this trend was the introduction of fentanyl analogues with faster and faster elimination. Fentanyl (8–10 hr elimination half-life) was followed by sufentanil (6–9 hr), alfentanil (2 hr), and remifentanil.4,5 Thus begat the “fashion” towards opioids with shorter and shorter half-lives. Nevertheless, postoperative pain is a significant problem after cardiac surgery.6 The use of intraoperative opioids with faster elimination causes diminished postoperative analgesia. Various routes and modalities of administering opioids to achieve postoperative analgesia (e.g. nurse-administered, patient-controlled, neuraxial) have been evaluated.7–9 In this issue of Anesthesiology,10 Murphy et al report a vastly different approach, and one which also departs substantially from the decades-long “fashion” of using opioids with faster elimination. For patients undergoing cardiac surgery, rather than using short-duration intraoperative and postoperative opioids, Murphy et al used a single dose of methadone at induction, to confer intraoperative and postoperative analgesia. Methadone, in addition to use for treating opiate addiction and acute and chronic pain, is an excellent intraoperative opioid which confers substantial postoperative analgesia for various surgical procedures.11 The novel and well-performed clinical investigation by Murphy et al demonstrates the value of intraoperative methadone use in adult cardiac surgery, extending its application and utility. The study evaluated 156 patients undergoing cardiac surgery (coronary artery bypass and/or valve surgery, or atrial septal defect repair, via median sternotomy) with cardiopulmonary bypass. Patients were randomized to receive approximately equi-effective doses of methadone (0.3 mg/kg) or fentanyl (12 μg/kg), with half the dose given at induction and the remainder infused over the next 2 hr. Patients postoperatively received intravenous morphine on request, and then oral opioids as soon as possible. The investigation is remarkable methodologically, for the frequency and thoroughness of intraoperative and postoperative data collection, including patient characteristics, operative and postoperative metrics, hemodynamics, postoperative troponin I and B-type natriuretic peptide concentrations, and postoperative complications, in addition to postoperative pain, analgesic requirements, and opioid-related complications. The results are similarly notable. In patients receiving methadone (vs fentanyl), the time until first postoperative morphine dose was longer, the 0–24 hr and 0–72 hr morphine requirements were lower, far fewer patients needed more than 20 mg morphine in the first 24 hr, and more patients left the hospital needing no postoperative morphine. In addition, despite the availability of as-needed morphine, pain scores (at rest and with coughing) were lower in the group of patients receiving methadone. In patients who received a single dose of methadone at induction, compared with those receiving fentanyl, postoperative pain severity was reduced 30 to 40%, postoperative morphine requirements were diminished approximately 40%, and patients’ satisfaction with pain management was significantly greater. There were no differences between methadone- and fentanyl-treated patients in the incidence of opioid-related side effects, extubation time, duration of intensive care unit or hospital stay, or complications. All clinical benefit, without any apparent disadvantage. As identified by Murphy et al, methadone in cardiac surgery patients can simplify perioperative opioid administration, enhance clinical recovery, and increase patient satisfaction. Methadone in cardiac surgery is definitely “anti-fashion”. Will it start a new trend?